Related Experiment Video
Updated: Apr 24, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease
Published on: June 30, 2018
Anti-VEGF Cancer Therapy in Nephrology Practice
1Department of Nephrology, Pitie-Salpetriere Hospital, 75013 Paris, France ; Department of Nephrology, Monceau Park International Clinic, 75017 Paris, France.
Abstract:
Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Kidney Transplant III: Nursing Management
Kidney Transplant I: Introduction
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

